Longeveron LLC, a regenerative medicine company developing cellular therapies, announced that it treated its first patient in the Company’s Phase 2b clinical trial evaluating the safety and efficacy of Longeveron

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field